MUC4 Mucin Interacts with and Stabilizes the HER2 Oncoprotein in Human Pancreatic Cancer Cells
- 1 April 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (7), 2065-2070
- https://doi.org/10.1158/0008-5472.can-07-6041
Abstract
MUC4, a high–molecular weight transmembrane glycoprotein, is overexpressed in pancreatic cancer and is implicated in its pathogenesis. It is a heterodimeric protein containing a large extracellular, heavily glycosylated subunit, MUC4α, and a transmembrane growth factor–like subunit, MUC4β. In the present study, we have shown the interaction of human MUC4 with the receptor tyrosine kinase HER2 in pancreatic adenocarcinoma cells by reciprocal coimmunoprecipitation and cocapping studies. MUC4 colocalized with HER2 at the cell surface and in the cytoplasm. Silencing of MUC4 by transient or stable expression of MUC4-targeted short-interfering RNA led to the down-regulation of HER2 with a concomitant decrease in its phosphorylated form (pY1248-HER2). Further analyses revealed that the MUC4-knockdown–mediated decrease in HER2 expression occurred due to the drop in the stability of the receptor. In MUC4-knockdown pancreatic cancer cells, we also observed a reduced phosphorylation of the focal adhesion kinase and p42/44 mitogen-activated protein kinase, which are downstream effector proteins in HER2 signaling. Our findings add a new dimension to MUC4 function as a modulator of cell signaling and provide mechanistic evidence for its role in pancreatic cancer progression. [Cancer Res 2008;68(7):2065–70]Keywords
This publication has 19 references indexed in Scilit:
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- MUC4 Mucin Potentiates Pancreatic Tumor Cell Proliferation, Survival, and Invasive Properties and Interferes with Its Interaction to Extracellular Matrix ProteinsMolecular Cancer Research, 2007
- Emerging Roles of MUC4 in Cancer: A Novel Target for Diagnosis and TherapyCancer Research, 2007
- MUC1 Oncoprotein Functions in Activation of Fibroblast Growth Factor Receptor SignalingMolecular Cancer Research, 2006
- MUC1 is a novel regulator of ErbB1 receptor traffickingOncogene, 2006
- Signaling through ERBB receptors: Multiple layers of diversity and controlCellular Signalling, 2006
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27kip, but does not activate mitogen-activated kinase or protein kinaseB/Akt pathwaysOncogene, 2002
- Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cellsOncogene, 2002
- Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient miceNature, 1995